Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Files Japan's First Rotavirus Vaccine; Will Japan Become Next Battleground For Vaccine Makers?

This article was originally published in PharmAsia News

Executive Summary

GlaxoSmithKline announced Nov. 30 it is applying for approval for its rotavirus vaccine Rotarix with Japan's Ministry of Health, Labor and Welfare. If approved, it will become the first vaccine in Japan to prevent rotavirus gastroenteritis, a leading cause of diarrhea-related deaths in children

You may also be interested in...



GSK Names Former Sanofi Executive As President Of Japanese Affiliate

GlaxoSmithKline has appointed Philippe Fauchet, formerly a senior vice president at Sanofi-Aventis, as the new president of GSK's Japanese subsidiary

GSK Names Former Sanofi Executive As President Of Japanese Affiliate

GlaxoSmithKline has appointed Philippe Fauchet, formerly a senior vice president at Sanofi-Aventis, as the new president of GSK's Japanese subsidiary

MHLW To Establish Advisory Committee To Drive Vaccine Policy

To streamline vaccination decision making and better respond to future infectious disease outbreaks, Japan's Ministry of Health, Labor and Welfare will request ¥15 million in the fiscal year 2010 budget to establish a vaccination policy advisory body based on the U.S. Advisory Committee on Immunization Practices

UsernamePublicRestriction

Register

LL006980

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel